Health

Results: 4993-5004 of 6177

Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

PR Newswire associated0

2024 SAFETY IN ACTION® CONFERENCE OPENS REGISTRATION

Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization

Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE. This will serve as the new fully automated LAAS (Lab As A Service) hub and provide clinical trials on a chip using latest microfluidic devices combined with the ability to print organoid bio-networks. Visit www.prepaire.com to learn more. (Photo: Business Wire)

Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids

ELIQUENT Life Sciences Announces Acquisition of European-Focused Regulatory Partner: RApport Global Strategic Services

PR Newswire associated0

More Than 350 Companies Increase Efficiency and Compliance with Veeva Training Solutions

Envision Pharma Group Welcomes Industry Veteran and HR Expert Carolyn Bartholdson as Chief People Officer

Takeda Named Global Top Employer for Seventh Consecutive Year

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

New Blue Shift Report From Arthur D. Little Assesses the Future of Synthetic Biology